ArticleGut2016

Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.

Tania M Welzel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.